Maxim Group Analysts Give Inovio Pharmaceuticals, Inc. (INO) a $12.00 Price Target
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given a $12.00 price target by stock analysts at Maxim Group in a report released on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target indicates a potential upside of 120.99% from the stock’s previous close.
Other equities analysts also recently issued reports about the company. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 3rd. Piper Jaffray Companies upgraded Inovio Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $14.00 price target for the company in a research note on Thursday, June 8th. Jefferies Group LLC reiterated a “neutral” rating and issued a $38.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. BNP Paribas reiterated a “neutral” rating and issued a $39.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. Finally, Zacks Investment Research upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price target for the company in a research note on Tuesday, July 11th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. Inovio Pharmaceuticals presently has an average rating of “Buy” and an average price target of $20.78.
Shares of Inovio Pharmaceuticals (NASDAQ:INO) opened at 5.43 on Wednesday. The company has a 50 day moving average price of $7.16 and a 200-day moving average price of $6.84. The firm’s market capitalization is $405.22 million. Inovio Pharmaceuticals has a 12 month low of $5.32 and a 12 month high of $9.95.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.31). The business had revenue of $10.40 million during the quarter, compared to the consensus estimate of $5.83 million. Inovio Pharmaceuticals had a negative return on equity of 65.97% and a negative net margin of 235.91%. The company’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.11) earnings per share. Equities research analysts expect that Inovio Pharmaceuticals will post ($1.06) EPS for the current fiscal year.
In other Inovio Pharmaceuticals news, Director David B. Weiner sold 8,000 shares of Inovio Pharmaceuticals stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $8.00, for a total value of $64,000.00. Following the completion of the transaction, the director now directly owns 740,956 shares in the company, valued at $5,927,648. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 10.60% of the company’s stock.
Several institutional investors have recently modified their holdings of INO. Bank of America Corp DE increased its position in shares of Inovio Pharmaceuticals by 14.6% in the first quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock valued at $188,000 after buying an additional 3,605 shares in the last quarter. American International Group Inc. increased its position in shares of Inovio Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 40,856 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 2,695 shares in the last quarter. Private Capital Advisors Inc. acquired a new position in shares of Inovio Pharmaceuticals during the second quarter valued at about $274,000. Metropolitan Life Insurance Co. NY increased its position in shares of Inovio Pharmaceuticals by 8.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 51,573 shares of the biopharmaceutical company’s stock valued at $341,000 after buying an additional 4,020 shares in the last quarter. Finally, State of Wisconsin Investment Board acquired a new position in shares of Inovio Pharmaceuticals during the second quarter valued at about $392,000. Institutional investors and hedge funds own 22.92% of the company’s stock.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.